Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening

References

• KuehnBMCDC estimates 300,000 US cases of Lyme disease annuallyJAMA2013310111024045727
   PubMed Web of Science ®Google Scholar
• VollmerSAFeilEJChuCYSpatial spread and demographic expansion of Lyme borreliosis spirochaetes in EurasiaInfect Genet Evol20131414715523219915
   PubMed Web of Science ®Google Scholar
• BrownsteinJSHolfordTRFishDEffect of climate change on Lyme disease risk in North AmericaEcohealth20052384619008966
   PubMedGoogle Scholar
• EspositoSBosisSSabatiniCTagliaferriLPrincipiNBorrelia burgdorferi infection and Lyme disease in childrenInt J Infect Dis201317e153e15823141587
   PubMed Web of Science ®Google Scholar
• BorchersATKeenCLHuntleyACGershwinMELyme disease: a rigorous review of diagnostic criteria and treatmentJ Autoimmun2015578211525451629
   PubMed Web of Science ®Google Scholar
• BockenstedtLKRadolfJDXenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it?Clin Infect Dis20145894694824523213
   PubMed Web of Science ®Google Scholar
• FengJWangTShiWIdentification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug libraryEmerg Microbes Infect20143e4926038747
   PubMed Web of Science ®Google Scholar
• BockenstedtLKGonzalezDGHabermanAMBelperronAASpirochete antigens persist near cartilage after murine Lyme borreliosis therapyJ Clin Invest20121222652266022728937
   PubMed Web of Science ®Google Scholar
• HodzicEFengSHoldenKFreetKJBartholdSWPersistence of Borrelia burgdorferi following antibiotic treatment in miceAntimicrob Agents Chemother2008521728173618316520
   PubMed Web of Science ®Google Scholar
• DiterichIRauterCKirschningCJHartungTBorrelia burgdorferi-induced tolerance as a model of persistence via immunosuppressionInfect Immun2003713979398712819085
   PubMed Web of Science ®Google Scholar
• SteereACSchoenRTTaylorEThe clinical evolution of Lyme arthritisAnn Intern Med19871077257313662285
   PubMed Web of Science ®Google Scholar
• BartholdSWde SouzaMSJanotkaJLSmithALPersingDHChronic Lyme borreliosis in the laboratory mouseAm J Pathol19931439599718362988
   PubMed Web of Science ®Google Scholar
• BabadyNEHallLAbbenyiATEvaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and JustOne stripsJ Clin Microbiol2010481749175220335412
   PubMed Web of Science ®Google Scholar
• EmbersMEBartholdSWBordaJTPersistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infectionPLoS One20127e2991422253822
   PubMed Web of Science ®Google Scholar
• HodzicEImaiDFengSBartholdSWResurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in micePLoS One20149e8690724466286
   PubMed Web of Science ®Google Scholar
• StraubingerRKSummersBAChangYFAppelMJPersistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatmentJ Clin Microbiol1997351111168968890
   PubMed Web of Science ®Google Scholar
• MarquesATelfordSR3rdTurkSPXenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human studyClin Infect Dis20145893794524523212
   PubMed Web of Science ®Google Scholar
• BrorsonØBrorsonSHScythesJMacAllisterJWierAMargulisLDestruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecyclineProc Natl Acad Sci U S A2009106186561866119843691
   PubMed Web of Science ®Google Scholar
• MiklossyJKasasSZurnADMcCallSYuSMcGeerPLPersisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosisJ Neuroinflammation2008511818171484
   PubMed Web of Science ®Google Scholar
• LantosPMAuwaerterPGWormserGPA systematic review of Borrelia burgdorferi morphologic variants does not support a role in chronic Lyme diseaseClin Infect Dis20145866367124336823
   PubMed Web of Science ®Google Scholar
• SharmaBBrownAVMatluckNEHuLTLewisKBorrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cellsAntimicrob Agents Chemother2015594616462426014929
   PubMed Web of Science ®Google Scholar
• FengJAuwaerterPGZhangYDrug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycyclinePLoS One201510e011720725806811
   PubMed Web of Science ®Google Scholar
• SapiEKaurNAnyanwuSEvaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferiInfect Drug Resist201149711321753890
   PubMedGoogle Scholar
• PaviaCInchiosaMAJrWormserGPEfficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H miceAntimicrob Agents Chemother20024613213411751123
   PubMed Web of Science ®Google Scholar
• WormserGPDanielsTJBittkerSCooperDWangGPaviaCSFailure of topical antibiotics to prevent disseminated Borrelia burgdorferi infection following a tick bite in C3H/HeJ miceJ Infect Dis201220599199421930606
   PubMed Web of Science ®Google Scholar
• PaviaCSWormserGPCulture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of CeftriaxoneAntimicrob Agents Chemother2014586701670325155590
   PubMed Web of Science ®Google Scholar
• LefasGChaconasGHigh-throughput screening identifies three inhibitor classes of the telomere resolvase from the Lyme disease spirocheteAntimicrob Agents Chemother2009534441444919596868
   PubMed Web of Science ®Google Scholar
• CornellKAPrimusSMartinezJAParveenNAssessment of methylthioadenosine/S-adenosylhomocysteine nucleosidases of Borrelia burgdorferi as targets for novel antimicrobials using a novel high-throughput methodJ Antimicrob Chemother2009631163117219376840
   PubMed Web of Science ®Google Scholar
• FengJShiWZhangSZhangYIdentification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collectionEmerg Microbes Infect20154e3126954881
   PubMed Web of Science ®Google Scholar
• FengJWeitnerMShiWZhangSSullivanDZhangYIdentification of additional anti-persister activity against Borrelia burgdorferi from an FDA drug libraryAntibiotics2015439727025631
   PubMedGoogle Scholar
• NygrenPLarssonRDrug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancerActa Oncol20145342742824160353
   PubMed Web of Science ®Google Scholar
• JahchanNSDudleyJTMazurPKA drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumorsCancer Discov201331364137724078773
   PubMed Web of Science ®Google Scholar
• WaghDPothineniVRInayathullahMLiuSKimKMRajadasJBorreliacidal activity of Borrelia metal transporter A (BmtA) binding small molecules by manganese transport inhibitionDrug Des Devel Ther20159805
   PubMed Web of Science ®Google Scholar
• KraiczyPWeigandJWichelhausTAIn vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferiAntimicrob Agents Chemother2001452486249411502519
   PubMed Web of Science ®Google Scholar
• HunfeldKPRodelRWichelhausTAIn vitro activity of eight oral cephalosporins against Borrelia burgdorferiInt J Antimicrob Agents20032131331812672576
   PubMed Web of Science ®Google Scholar
• VeinovicGCerarTStrleFIn vitro susceptibility of European human Borrelia burgdorferi sensu stricto strains to antimicrobial agentsInt J Antimicrob Agents20134128829123312603
   PubMed Web of Science ®Google Scholar
• FengJWangTZhangSShiWZhangYAn optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferiPLoS One20149e11180925365247
   PubMed Web of Science ®Google Scholar
• FengJWangTShiWIdentification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug libraryEmerg Microbes Infect20143e4926038747
   PubMed Web of Science ®Google Scholar
• MarquesAChronic Lyme disease: a reviewInfect Dis Clin North Am200822341360viiviii18452806
   PubMed Web of Science ®Google Scholar
• TerekhovaDSartakovaMLWormserGPSchwartzICabelloFCErythromycin resistance in Borrelia burgdorferiAntimicrob Agents Chemother2002463637364012384380
   PubMed Web of Science ®Google Scholar
• KannanKKanabarPSchryerDThe general mode of translation inhibition by macrolide antibioticsProc Natl Acad Sci U S A2014111159581596325349425
   PubMed Web of Science ®Google Scholar
• SteelHCTheronAJCockeranRAndersonRFeldmanCPathogen-and host-directed anti-inflammatory activities of macrolide antibioticsMediators Inflamm2012201258426222778497
   PubMed Web of Science ®Google Scholar
• ShinkaiMHenkeMORubinBKMacrolide antibiotics as immunomodulatory medications: proposed mechanisms of actionPharmacol Ther200811739340518289694
   PubMed Web of Science ®Google Scholar
• LeachKLBricknerSJNoeMCMillerPFLinezolid, the first oxazolidinone antibacterial agentAnn N Y Acad Sci20111222495421434942
   PubMed Web of Science ®Google Scholar
• Van BambekeFMacrolides and ketolidesVinksADerendorfHMoutonJWFundamentals of Antimicrobial Pharmacokinetics and PharmacodynamicsNew York, NYSpringer2014257278
   Google Scholar
• Yuan-shuQQi-nanWYu-fuJPharmacokinetic study of leucomycin in healthy volunteers [J]Zhongguo Kang Sheng Su Za Zhi19902008
   Google Scholar
• LinAHMurrayRWVidmarTJMarottiKRThe oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycinAntimicrob Agents Chemother199741212721319333036
   PubMed Web of Science ®Google Scholar
• DrydenMSLinezolid pharmacokinetics and pharmacodynamics in clinical treatmentJ Antimicrob Chemother201166Suppl 4iv7iv1521521707
   PubMed Web of Science ®Google Scholar
• KeelRASchaeftleinAKloftCPharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosisAntimicrob Agents Chemother2011553393339821518837
   PubMed Web of Science ®Google Scholar
• ViaggiBPaoloADDanesiRLinezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokineticsScand J Infect Dis20114372172721585240
   PubMed Web of Science ®Google Scholar
• Kutscha-LissbergFHeblerUMuhrGKöllerMLinezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococciAntimicrob Agents Chemother2003473964396614638510
   PubMed Web of Science ®Google Scholar
• Pérez-ArnaizCBustoNLealJMGarcíaBNew insights into the mechanism of the DNA/doxorubicin interactionJ Phys Chem B20141181288129524417409
   PubMed Web of Science ®Google Scholar
• KizekRAdamVHrabetaJAnthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advancesPharmacol Ther2012133263921839775
   PubMed Web of Science ®Google Scholar
• DanesiRFogliSGennariAContePDel TaccaMPharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugsClin Pharmacokinet20024143144412074691
   PubMed Web of Science ®Google Scholar
• PucciMJWilesJABacterial Topoisomerase Inhibitors: Quinolones and BeyondAntimicrobialsNew York, NYSpringer2014307326
   Google Scholar
• StassHKubitzaDPharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in manJ Antimicrob Chemother199943Suppl B839010382880
   PubMed Web of Science ®Google Scholar
• MalikMDrlicaKMoxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicolAntimicrob Agents Chemother2006502842284416870782
   PubMed Web of Science ®Google Scholar
• NikiYPharmacokinetics and safety assessment of tosufloxacin tosilateJ Infect Chemother2002811811957114
   PubMedGoogle Scholar
• FernandesRAmadorPPrudêncioCβ-Lactams: chemical structure, mode of action and mechanisms of resistanceRev Med Microbiol201324717
   Web of Science ®Google Scholar
• GuayDRCefdinir: an expanded-spectrum oral cephalosporinAnn Pharmacother2000341469147711144705
   PubMed Web of Science ®Google Scholar
• BerezinSKValinomycin as a classical anionophore: mechanism and ion selectivityJ Membr Biol201524871372625736817
   PubMed Web of Science ®Google Scholar
• Zaldívar-MachorroVJLópez-OrtizMDemarePReglaIMuñoz-ClaresRAThe disulfiram metabolites S-methyl-N,N- diethyldithiocarbamoyl sulfoxide and S-methyl-N,N-diethylthiocarbamoyl sulfone irreversibly inactivate betaine aldehyde dehydrogenase from Pseudomonas aeruginosa, both in vitro and in situ, and arrest bacterial growthBiochimie20119328629520933050
   PubMed Web of Science ®Google Scholar